12:22 PM EDT, 10/27/2026 (MT Newswires) -- The US Food and Drug Administration approved Xbrane Biopharma's (XBRANE.ST) Lucamzi, a biosimilar to Lucentis. The Swedish biopharmaceutical company said Tuesday that Lucamzi is intended to treat wet age-related macular degeneration and other serious eye conditions. A phase 3 clinical study involving 582 patients showed equivalent efficacy and comparable safety to the reference product. Following the approval, Xbrane plans to launch the drug in the US in 2027 with its partners.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.